Dyslipidemia Signs and Symptoms

Signs and Symptoms

Definition

An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
Increase in serum concentration of TC, LDL, TG or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

Depends on the type of dyslipidemia
Hereditary disorders associated with primary dyslipidemia include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, obstructive liver disease, Cushing’s syndrome, metabolic syndrome, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)

Once-weekly GLP-1 receptor agonists in T2DM: Metabolic control with cardiovascular benefit

11 Apr 2022

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiorenal events. The REWIND trial aimed to assess the impact of dulaglutide on cardiovascular outcomes in T2DM patients with increased cardiovascular risk. As part of an Eli Lilly-sponsored virtual event held in September 2021, Professor Alice Pik-Shan Kong (The Chinese University of Hong Kong) presented the main results of the REWIND trial.

SGLT2 inhibitors slow CKD progression, may delay dialysis

Prof. Kai-Uwe Eckardt, 13 Oct 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been dubbed “surprise blockbusters” because of their paradigm-shifting cardiorenal benefits in chronic kidney disease (CKD). At an industry-sponsored symposium during the 18^th Congress of Asian Society of Transplantation (CAST 2023), Professor Kai-Uwe Eckardt of the Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Germany, reviewed findings from randomized controlled trials (RCTs) and a recent meta-analysis showing reductions in risk of kidney disease progression and acute kidney injury (AKI) associated with these agents. He also discussed how these effects potentially delay the need for dialysis and kidney transplantation.

TICO backs ticagrelor alone in ACS post-PCI

Pearl Toh, 23 Apr 2020

Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.